MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Biogen has said it hopes new “real world” data will ensure patients are not put off taking its key multiple sclerosis drug, Tecfidera because of stomach problems that can occur early in treatment.